JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

0:00 - Introduction
0:35 - 3 Horsemen: Pain, Inflammation, Destruction
4:03 - Reversing Osteoarthritis
6:29 - The Most Impressive Result

References
[Study 729] Qin H, Yu J, Yu H, et al. Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metab. 2026;38:582-597. doi:10.1016/j.cmet.2026.01.008

Funding/Conflicts: Public Funding: From the study, the project was supported by National Natural Science Foundation of China grants, Shenzhen Medical Research Funds, and Shenzhen Science and Technology Research Funding; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no industry funding source was reported, and the authors declared no competing interests.

[Study 730] Meurot C, Martin C, Sudre L, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022;12:1567. doi:10.1038/s41598-022-05323-7

Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no direct industry funding source was reported, but several authors were affiliated with 4P-Pharma and/or 4Moving Biotech, and conflicts included personal fees from multiple pharmaceutical companies, a TRB Chemedica grant, leadership roles in 4Moving Biotech and 4P Pharma, and patents owned by 4Moving Biotech and Sorbonne University for the use of GLP-1 analogs in osteoarthritis.

[Study 731] Zhu H, Zhou L, Wang Q, et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023;82:1218-1226. doi:10.1136/ard-2023-223845

Funding/Conflicts: Public Funding: From the study, the work was funded by the Shanghai Shen Kang Hospital Development Centre, Clinical Research Plan of SHDC, and the National Natural Science Foundation of China; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no industry funding source was reported, and the authors declared no competing interests.

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.